Diabetes mellitus (DM) represents a series of chronic metabolic conditions, biochemically characterized by hyperglycemia resulting from insulin deficiency due to pancreatic β-cell damage (type 1 DM) or peripheral tissue insulin resistance (type 2 DM) (
1). Additionally, several other specific types of DM have been classified under a broad category termed maturity-onset diabetes of the young (MODY) (
2). Type 2 diabetes mellitus (T2DM), also called non-insulin-dependent DM, is associated with insulin resistance and progressive non-autoimmune β-cell dysfunction (
3). While T2DM has long been the most prevalent form of DM among young adults (formerly called adult-onset diabetes mellitus), an increasing trend of T2DM and prediabetic dysglycemia has been noticeably observed among children and adolescents in recent years. Whether it is DM or prediabetes, exposure to chronic hyperglycemia increases the risk of microvascular and long-term macrovascular complications. It is noteworthy that reductions in mortality among people with DM, associated with current antidiabetic medications, will increase the lifetime accumulation of T2DM complications and morbidities worldwide (
4). All these issues, plus the fact that the atherosclerotic process may originate in childhood and adolescence, highlight the necessity of obesity and DM screening among children (
5-
7) (
Table 1). Given the importance of DM and obesity, this narrative review aimed to address the optimal screening and control of childhood obesity as the main strategies for dealing with the comorbidities of T2DM.